11月11日盘中，医药巨头阿斯利康英股股价一度上涨2.5%至134.6英镑，创下历史新高。其市值接近2100亿英镑（2820亿美元），进一步巩固了其 作为英股第一大权重股地位。 此外，10月达成的美国药品定价协议也为股价带来额外提振。该协议缓解了市场对美国医药政策不确定性的担忧。作为阿斯利康最大收入来源， 美国市场贡献公司总销售额超40%，其政策环境对股价具有显著影响。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责 任自负。 作为英国富时100指数的第一大权重股，阿斯利康的强势表现对大盘形成显著拉动。在英国就业数据增强央行降息预期的共同推动下，富时100指 数盘中亦上涨1.1%，同步创出历史新高。 本轮上涨主要受阿斯利康上周发布的超预期业绩支撑。财报显示，受创新药需求持续拉动，公司前三季度总营收同比增长11%，核心每股收益增 长15%，各业务板块及主要区域市场均实现稳健增长。 ...

Investment Rating - Industry Rating: Outperform the Market (maintained rating) [5] Core Viewpoints - The Trump administration is considering strict restrictions on medicines from China, which could significantly impact the American pharmaceutical industry and the availability of various treatments [10][11] - The proposed executive order draft includes mandatory reviews of acquisitions by U.S. pharmaceutical companies of experimental drugs from Chinese firms and stricter scrutiny of clinical trial data from China [15][10] - Major pharmaceutical companies like Pfizer and AstraZeneca oppose these restrictions, as they benefit from cost-effective Chinese biotech assets [2][4] - The likelihood of the executive order being enacted is low due to its early discussion stage and the lack of positive feedback [3][5] - Even if the order is implemented, there are various countermeasures available, and the overall impact is expected to be manageable [5] Summary by Sections Section 1: Proposed Restrictions - The draft executive order aims to impose strict controls on Chinese medicines, requiring mandatory reviews for acquisitions and higher scrutiny on clinical data from China [10][15] - The order is seen as a response to concerns about national security and the competitive threat posed by China's biotech sector [11][10] Section 2: Industry Reactions - Major pharmaceutical companies are lobbying against the proposed restrictions, emphasizing the benefits of collaboration with Chinese biotech firms [2][4] - The lobbying efforts highlight a divide between investors tied to the Trump administration and established pharmaceutical companies [10][11] Section 3: Feasibility and Impact - The report suggests that the executive order's implementation is unlikely due to political and practical challenges [3][5] - The pharmaceutical industry is expected to adapt to any potential restrictions, maintaining a focus on global collaboration and innovation [5]

Group 1: Pharmaceutical Companies and Products - 63 pharmaceutical companies have been exposed for serious credit violations, with 63 companies rated as "particularly serious" or "serious" by the National Medical Insurance Administration [1] - Junshi Biosciences announced positive results from a Phase III clinical trial of JS005 for moderate to severe plaque psoriasis, planning to submit a marketing application soon [1] - Sanofi's teplizumab injection has been approved in China for delaying the progression of type 1 diabetes in patients aged 8 and above [2] Group 2: Corporate Actions - Yingke Medical adjusted its share repurchase price limit from RMB 26.51 to RMB 41.88 per share, effective from September 8, 2025, with a total repurchase fund of RMB 80 million to 120 million [3] - Qidi Pharmaceutical plans to change its name to "Guhan Health Industry Group Co., Ltd." and will revise its articles of association accordingly [4] - Jiuan Medical intends to cancel 9.77 million shares, which is 2.06% of its total share capital, as part of a strategy to enhance shareholder returns [5] Group 3: Market Movements and Regulations - Xiangrikui is planning to acquire controlling stakes in Xi Pu Materials and 40% of Beid Pharmaceutical, leading to a temporary suspension of its stock [6] - Beijing has launched a free HPV vaccination program for new first-year junior high school girls, aiming to increase vaccination rates [7][8] - Two studies on iza-bren (EGFR×HER3 dual antibody ADC) have been selected for the official news release program at the 2025 WCLC, highlighting its clinical significance [9] Group 4: Shareholder Actions - Chengda Pharmaceutical announced that a shareholder plans to reduce their stake by up to 7.27% within three months [10] - Kangchen Pharmaceutical's controlling shareholder plans to reduce their stake by up to 3% between September 29 and December 28, 2025, due to personal funding needs [11]

Group 1 - The U.S. Secretary of Commerce, Gina Raimondo, stated that a trade surplus indicates that the U.S. is being "sold out" [1] - The European Union agreed to the deal primarily due to the pharmaceutical and automotive industries [1] - The EU does not want the U.S. to drive pharmaceutical companies out of Europe [1] Group 2 - Former President Trump is expected to announce a new pharmaceutical policy within the next two weeks [1] - A significant tariff will be imposed if drugs are not produced in the U.S. [1]

Investment Rating - The industry investment rating is "Positive" [1] Core Views - The report highlights that the pharmaceutical distribution sector is under pressure but is expected to see a recovery in profitability [3][6] - The report emphasizes the importance of new business models such as CSO and health device distribution, which are anticipated to support revenue growth [7] Summary by Sections Market Review - From January 1, 2025, to May 8, 2025, the pharmaceutical distribution index declined by 2.44%, underperforming the pharmaceutical and biotechnology index by 3.73 percentage points [4] - The market capitalization of pharmaceutical distribution in Q1 2025 was 1.5 billion, accounting for 0.05% of the total A-share fund holdings, showing a decrease from the previous quarter [4][20] Financial Analysis - Revenue growth for 2024 is projected at an average of 0.52%, a significant decline of 9.04 percentage points year-on-year. Major companies like China National Pharmaceutical and China Medicine are expected to experience negative growth [5][24] - In Q1 2025, the average revenue growth rate for key companies in pharmaceutical distribution was -0.11%, but this represents an improvement of 1.31 percentage points year-on-year [5][24] - The average net profit growth rate for key companies in Q1 2025 was 4.83%, an increase of 13.95 percentage points compared to the previous year [29][40] - The average gross profit margin for Q1 2025 was 8.33%, down 0.32 percentage points year-on-year, continuing a downward trend influenced by centralized procurement and drug pricing policies [32][40] Investment Recommendations - The report recommends focusing on leading companies in the pharmaceutical distribution sector, particularly those with strong capabilities in hospital payment recovery and innovative distribution channels. Key recommendations include Shanghai Pharmaceuticals, Jiuzhoutong, Baiyang Pharmaceuticals, and Zhongyao Holdings, with a watch on China National Pharmaceutical, Guoyao Holdings, and Liuyao Group [7][55]